CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 121,424	$ 81,467
Short-term marketable securities	94,789	211,474
Receivables from collaborative arrangements	14,001	15,868
Amounts due from TRC, LLC	43,773	53,799
Prepaid clinical and development services	13,242	20,374
Other prepaid and current assets	9,943	10,359
Total current assets	297,172	393,341
Property and equipment, net	16,003	16,422
Operating lease assets	40,718	43,260
Equity in net assets of TRC, LLC	45,086	12,750
Restricted cash	833	833
Other assets	3,297	2,451
Total assets	403,109	469,057
Current liabilities:
Accounts payable	8,900	6,775
Accrued personnel-related expenses	8,635	35,238
Accrued clinical and development expenses	20,607	28,799
Accrued general and administrative expenses	3,854	6,048
Accrued interest payable	5,808	3,974
Current portion of non-recourse notes due 2035, net	12,530	19,334
Operating lease liabilities	1,016	9,867
Deferred revenue	2,902	11,523
Other accrued liabilities	1,830	2,013
Total current liabilities	66,082	123,571
Convertible senior notes due 2023, net	227,767	226,963
Non-recourse notes due 2035, net	375,570	372,873
Long-term operating lease liabilities	54,353	47,220
Long-term deferred revenue	320	348
Other long-term liabilities	2,609	1,833
Commitments and contingencies
Shareholders' Deficit
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 73,698 and 64,328 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	1	1
Additional paid-in capital	1,370,402	1,222,818
Accumulated other comprehensive income	14	47
Accumulated deficit	(1,694,009)	(1,526,617)
Total shareholders' deficit	(323,592)	(303,751)
Total liabilities and shareholders' deficit	$ 403,109	$ 469,057